Table 1.
Demographics and clinical characteristics for participants
| Characteristic | Baseline | Follow-Up | P Value |
|---|---|---|---|
| Men (%) | 12 (25%) | — | |
| Randomized to losartan in clinical trial, % | 31 (64.6%) | — | |
| Age, yr | 45.6±8.8 | 55.0±9.2 | — |
| Diabetes duration, yr | 14.6±5.0 | 23.9±5.2 | — |
| GFR, ml/min | 156±58 | 133±46 | 0.006 |
| ACR, mg/g | 15 (6–45) | 27 (17–124) | 0.002 |
| Normoalbuminuria | 32 (66.7%) | 25 (52.1%) | 0.01a |
| Microalbuminuria | 15 (31.3%) | 15 (31.3%) | |
| Macroalbuminuria | 1 (2.1%) | 8 (16.7%) | |
| Systolic BP, mm Hg | 120±13 | 119±14 | 0.55 |
| Diastolic BP, mm Hg | 77±7 | 71±9 | <0.001 |
| Body mass index, kg/m2 | 35.7±6.3 | 34.7±7.3 | 0.07 |
| HbA1c, % | 9.1±2.0 | 9.7±2.0 | 0.10 |
| Use of insulin, % | 18 (37.5%) | 28 (58.3%) | 0.03a |
| Use of antihypertensives, % | 39 (81.3%) | 32 (66.7%) | >0.99a |
| Use of renin-angiotensin system blockers, % | 37 (77.1%) | 29 (60.4%) | 0.80a |
| Use of lipid-lowering agents, % | 14 (29.2%) | 27 (56.3%) | 0.47a |
| Time between biopsies, yr | 9.4±1.3 | — | |
| Time between GFR measurements, yr | 9.3±1.3 | — | |
Data are mean±SD for continuous measures and numbers with percentages for categorical variables. Normoalbuminuria defined as ACR<30 mg/g; microalbuminuria defined as ACR 30–300 mg/g; macroalbuminuria defined as ACR>300 mg/g.
a
P values for paired t tests except for chi-squared test.